Clin Cancer Res: Entinot United Pim Single Anti-Treatment ICII Refracidable NSCLC

Anti-PD-1/PD-L1 immunotherapy, as a single-drug therapy or in combination with chemotherapy, significantly improved the prognostic prognostication of patients with non-small cell lung cancer (NSCLC), at present, Navu monoanti and Artju monoantigen have been approved for metastasis NSCLC, durvalumab has been approved for local late NSCLC, Pym monoantigen has been approved in metastasis and local late NSCLC.
, however, even though so many drugs are available, there are still some patients who do not respond to the initial treatment of PD-1 or eventually or have access to the drug.
, new treatments are urgently needed to treat NSCLC, an immuno-checkpoint inhibitor, and to identify biomarkers that can be used to guide personalized treatment.
-on-the-surface genetic therapy, including histogenetic deacetylase inhibitors, or can work in synergy with PD-1 blocking to overcome drug resistance.
this paper reports the results of treatment with Pym monoant anti-entinote in patients with anti-PD-(L)1 drug-resistant/refractic non-small cell lung cancer in ENCORE 601 trials.
ENCORE 601 trial extended the queue to include patients with NSCLC who had progressed in the course of treatment with immuno-checkpoint inhibitors in the past.
end point of the Phase 2 extended queue is the Overall Mitigation Rate (ORR), which also summarizes the security, toerability, and exploratory endpoints.
71 of the 76 patients treated for changes in maximum tumor load and tumor volume over time could be included in the efficacy assessment.
ORR assessed by the IrRECIST was 9.2% (95% CI 3.8 to 18.1) and did not meet the pre-set positive threshold.
DOR was 10.1 months (95% CI 3.9-NE), 6 months PFS was 22%, the medium PFS was 2.8 months (95% CI 1.5 to 4.1), and the medium OS was 11.7 months (95% CI 7.6 to 13.4).
patients with higher baseline levels of acetylized lysine in exonymized blood immunocells who expressed exoglominal blood after treatment.
the expression levels of PD-L1 and IFN gene expression in baseline tumors were independent of how much benefit was gained.
41% of patients had treatment-related ≥ level 3 adverse events.
The prognosis (PFS and OS) of the group according to the classical number of mononucleocytes in general, in NSCLC patients, Entenot combined Pym monoantigen did not reach the main effective endpoint, but about 9% of patients obtained objective and effective clinical significance from the treatment.
neither drug showed new toxicity, including immune-related adverse events.
will continue to assess the relationship between monocyte levels and therapeutic responses.
。